Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ciliatech
19 patients with primary open angle glaucoma (POAG) refractory to topical medical therapy were operated in late 2020 and a novel interposition supraciliary device implanted.
These patients reached 6 months follow-up and the original study had to be interrupted.
This observational study prolonges follow-up to 36 months
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients who were implanted in this center with the novel supraciliary interposition device under the scope of clinical trial NCT03736655
You may not be if
if cannot assist to all future follow-up visits
Clareo Health | Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma
